Earnings Preview: Lucid Diagnostics
Portfolio Pulse from Benzinga Insights
Lucid Diagnostics (NASDAQ:LUCD) is scheduled to release its quarterly earnings report on March 25, 2024, with an expected EPS of $-0.26. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows that Lucid Diagnostics has previously beaten EPS estimates, leading to significant share price movements. Currently, the stock is trading at $1.11, reflecting a 26.43% decrease over the last year.
March 22, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lucid Diagnostics is expected to report an EPS of $-0.26 for the upcoming quarter. Historical performance shows positive stock price movement following earnings beats.
Given Lucid Diagnostics' history of surpassing EPS estimates and the subsequent positive impact on its stock price, there is a potential for short-term price appreciation if the company beats the EPS estimate again and provides positive guidance. However, the overall negative trend over the past year suggests caution.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100